LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Higher sitting time increases the risk of all‐cause, cancer‐specific, and noncancer mortality

Photo from wikipedia

Future Considerations Although the blood test/PLCOm2012 model could be implemented as a laboratory-developed test in the near future, Food and Drug Administration approval would likely require an evaluation through a… Click to show full abstract

Future Considerations Although the blood test/PLCOm2012 model could be implemented as a laboratory-developed test in the near future, Food and Drug Administration approval would likely require an evaluation through a prospective clinical trial. However, the test may not be ready for wide distribution yet, says Roy S. Herbst, MD, PhD, the Ensign Professor of Medicine, chief of medical oncology, and deputy director for clinical affairs at the Yale Cancer Center and Smilow Cancer Hospital and assistant dean for translational research at the Yale School of Medicine in New Haven, Connecticut. “Who we screen now is based strictly on ageand smoking-related criteria,” Dr. Herbst says. “This molecular test can help identify individuals who are at a higher risk. This is still a small study in a selected subgroup. It is very encouraging, however, and generates a hypothesis for future studies.”

Keywords: higher sitting; sitting time; test; risk; medicine; cancer

Journal Title: Cancer
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.